KCNF1
KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Overview
Regulatory alpha-subunit of the voltage-gated potassium (Kv) channel which, when coassembled with KCNB1 or KCNB2, can modulate their expression and their gating kinetics by acting on deactivation upon repolarisation and inactivation during maintained depolarisation. Accelerates inactivation but has relatively little effect on deactivation. Coexpression with KCNB1 or KCNB2 markedly slows inactivation.
Open Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.69, somatic mutation 0.23, clinical 0.76).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 1 · What it is
KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 2 · What goes wrong in cancer
Regulatory alpha-subunit of the voltage-gated potassium (Kv) channel which, when coassembled with KCNB1 or KCNB2, can modulate their expression and their gating kinetics by acting on deactivation upon repolarisation and inactivation during maintained depolarisation.
- 3 · How drugs use it
No product in this corpus aims at KCNF1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:6246 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H3M0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000162975 (association with cancer (MONDO_0004992) 0.51; (GraphQL API, CC0))
Biology
Regulatory alpha-subunit of the voltage-gated potassium (Kv) channel which, when coassembled with KCNB1 or KCNB2, can modulate their expression and their gating kinetics by acting on deactivation upon repolarisation and inactivation during maintained depolarisation. Accelerates inactivation but has relatively little effect on deactivation. Coexpression with KCNB1 or KCNB2 markedly slows inactivation. Each modulatory subunit has its own specific properties of regulation, and can lead to extensive inhibitions, to large changes in kinetics, and/or to large shifts in the voltage dependencies of the inactivation process. The gating kinetics depends on the nature and stoichiometry of the associated regulatory sunbunit. Fails to produce a potassium current when expressed alone. Location: Cell membrane (UniProt). Locus 2p25.1 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KCNF1" OR ABSTRACT:"KCNF1" OR TITLE:"potassium voltage-gated channel modifier subfamily F member 1" OR ABSTRACT:"potassium voltage-gated channel modifier subfamily F member 1" OR TITLE:"Voltage-gated potassium channel regulatory subunit KCNF1" OR ABSTRACT:"Voltage-gated potassium channel regulatory subunit KCNF1" OR TITLE:"Kv5.1" OR ABSTRACT:"Kv5.1" OR TITLE:"kH1" OR ABSTRACT:"kH1" OR TITLE:"IK8" OR ABSTRACT:"IK8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNF1, not a curated reading list.